Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography.

Grübler, Martin Robert; Delgado, Graciela; Kleber, Marcus; Hartaigh, Bríain Ó; de Boer, Rudolf Allert; Verheyen, Nicolas; Keppel, Martin; Schmid, Johannes; Siontis, George C.M.; Räber, Lorenz; Pieske, Burkert; Pilz, Stefan; Tomaschitz, Andreas; März, Winfried (2020). Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography. The American journal of cardiology, 127, pp. 9-15. Elsevier 10.1016/j.amjcard.2020.04.017

[img]
Preview
Text
Effect of Galectin 3 on Aldosterone-associated Risk of cardiovascular mortality in patients undergoing coronary angiography.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (360kB) | Preview

Recent experimental studies have suggested that galectin-3 has an interaction with aldosterone, and modifies its adverse effects. We therefore aimed to elucidate whether the relationship between plasma aldosterone concentrations (PACs) and long-term fatal cardiovascular (CV) events would depend on plasma galectin-3 levels. A total of 2,457 patients (median age: 63.5 [interquartile range (IQR) = 56.3 to 70.6] years, 30.1% women) from the LUdwigshafen RIsk and Cardiovascular Health study, with a median follow-up of 9.9 (IQR = 8.5 to 10.7) years, were included. We tested the interaction between aldosterone and galectin-3 for CV-mortality using a multivariate Cox proportional hazard model, reporting hazard ratios (HRs) with 95% confidence intervals (95%CIs). Adjustments for multiple CV risk factors as well as medication use were included. Mean PAC was 79.0 (IQR = 48.0 to 124.0) pg/ml and there were 558 (16.8%) CV deaths. There was a significant interaction between PAC and galectin-3 (p = 0.021). When stratifying patients by the median galectin-3, there was a significant association between aldosterone and CV-mortality for those above (HR per 1 standard deviation = 1.14; 95%CI [1.01 to 1.30], p = 0.023), but not below the cut-off value (HR per 1 standard deviation = 1.00; 95%CI [0.87 to 1.15], p = 0.185). In conclusion, the current study demonstrates for the first time a modifying effect of galectin-3 on the association between aldosterone and CV-mortality risk in humans. These findings indicate that galectin-3 is an intermediate between aldosterone and adverse outcomes.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Siontis, Georgios and Räber, Lorenz

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0002-9149

Publisher:

Elsevier

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

04 Dec 2020 09:46

Last Modified:

19 Apr 2021 07:10

Publisher DOI:

10.1016/j.amjcard.2020.04.017

PubMed ID:

32418719

BORIS DOI:

10.7892/boris.147532

URI:

https://boris.unibe.ch/id/eprint/147532

Actions (login required)

Edit item Edit item
Provide Feedback